Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 331 | 2023 | 2207 | 20.620 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 166 | 2023 | 964 | 16.530 |
Why?
|
ErbB Receptors | 67 | 2023 | 557 | 6.790 |
Why?
|
Antineoplastic Agents | 100 | 2023 | 1891 | 6.260 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 91 | 2023 | 1359 | 5.970 |
Why?
|
Carcinoma, Small Cell | 103 | 2008 | 159 | 5.280 |
Why?
|
Quinazolines | 37 | 2016 | 241 | 4.710 |
Why?
|
Small Cell Lung Carcinoma | 13 | 2023 | 77 | 4.670 |
Why?
|
Protein Kinase Inhibitors | 32 | 2023 | 788 | 3.480 |
Why?
|
Paclitaxel | 28 | 2011 | 192 | 2.660 |
Why?
|
Carboplatin | 24 | 2019 | 139 | 2.420 |
Why?
|
Guanine | 11 | 2007 | 76 | 2.220 |
Why?
|
Glutamates | 11 | 2007 | 59 | 2.030 |
Why?
|
Molecular Targeted Therapy | 13 | 2019 | 348 | 2.030 |
Why?
|
Neoplasm Staging | 63 | 2018 | 1177 | 1.960 |
Why?
|
Adenocarcinoma | 30 | 2017 | 797 | 1.890 |
Why?
|
Humans | 510 | 2023 | 115888 | 1.720 |
Why?
|
Antibodies, Monoclonal | 42 | 2018 | 1262 | 1.660 |
Why?
|
Biomarkers, Tumor | 35 | 2021 | 1045 | 1.600 |
Why?
|
Neoadjuvant Therapy | 9 | 2023 | 301 | 1.590 |
Why?
|
Deoxycytidine | 11 | 2004 | 140 | 1.580 |
Why?
|
Taxoids | 13 | 2013 | 94 | 1.510 |
Why?
|
Antimetabolites, Antineoplastic | 9 | 2007 | 83 | 1.460 |
Why?
|
Skin Neoplasms | 55 | 2010 | 760 | 1.450 |
Why?
|
Mutation | 29 | 2023 | 3369 | 1.400 |
Why?
|
Gene Expression Regulation, Neoplastic | 22 | 2018 | 1143 | 1.370 |
Why?
|
Clinical Trials as Topic | 48 | 2019 | 945 | 1.360 |
Why?
|
Receptor, ErbB-2 | 11 | 2019 | 302 | 1.350 |
Why?
|
Lymphoma | 47 | 1991 | 177 | 1.340 |
Why?
|
Combined Modality Therapy | 52 | 2023 | 1128 | 1.330 |
Why?
|
Antineoplastic Agents, Phytogenic | 10 | 2007 | 181 | 1.300 |
Why?
|
Etoposide | 25 | 2023 | 149 | 1.260 |
Why?
|
Survival Analysis | 33 | 2019 | 1221 | 1.170 |
Why?
|
Carcinoma, Squamous Cell | 21 | 2023 | 577 | 1.170 |
Why?
|
Sezary Syndrome | 36 | 1996 | 43 | 1.140 |
Why?
|
Cisplatin | 28 | 2018 | 263 | 1.120 |
Why?
|
Drug Resistance, Neoplasm | 19 | 2023 | 638 | 1.100 |
Why?
|
Protein-Tyrosine Kinases | 9 | 2023 | 394 | 1.100 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 9 | 2010 | 40 | 1.090 |
Why?
|
Mycosis Fungoides | 38 | 1996 | 61 | 1.060 |
Why?
|
Erlotinib Hydrochloride | 12 | 2015 | 65 | 1.030 |
Why?
|
Aged | 135 | 2023 | 19295 | 1.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 11 | 2023 | 664 | 1.000 |
Why?
|
Bradykinin | 9 | 2005 | 46 | 0.990 |
Why?
|
In Situ Hybridization, Fluorescence | 21 | 2018 | 310 | 0.990 |
Why?
|
Vinblastine | 7 | 2003 | 61 | 0.980 |
Why?
|
Immunotherapy | 13 | 2020 | 480 | 0.960 |
Why?
|
Precision Medicine | 4 | 2018 | 356 | 0.960 |
Why?
|
Middle Aged | 164 | 2023 | 27079 | 0.950 |
Why?
|
Proto-Oncogene Proteins | 15 | 2023 | 609 | 0.910 |
Why?
|
Folic Acid Antagonists | 4 | 2005 | 8 | 0.900 |
Why?
|
Prognosis | 52 | 2019 | 3342 | 0.900 |
Why?
|
Angiogenesis Inhibitors | 8 | 2018 | 216 | 0.880 |
Why?
|
Tumor Cells, Cultured | 29 | 2014 | 850 | 0.860 |
Why?
|
Male | 200 | 2023 | 56121 | 0.840 |
Why?
|
Gene Dosage | 10 | 2018 | 127 | 0.840 |
Why?
|
Female | 192 | 2023 | 60075 | 0.810 |
Why?
|
Survival Rate | 23 | 2020 | 1653 | 0.800 |
Why?
|
Neutropenia | 11 | 2022 | 127 | 0.790 |
Why?
|
Liposomes | 2 | 2022 | 149 | 0.780 |
Why?
|
Immunohistochemistry | 24 | 2020 | 1643 | 0.770 |
Why?
|
Gene Amplification | 9 | 2019 | 96 | 0.760 |
Why?
|
Pemetrexed | 13 | 2016 | 27 | 0.750 |
Why?
|
Receptor Protein-Tyrosine Kinases | 10 | 2022 | 225 | 0.740 |
Why?
|
Chemotherapy, Adjuvant | 10 | 2015 | 334 | 0.720 |
Why?
|
Enzyme Inhibitors | 9 | 2016 | 758 | 0.720 |
Why?
|
Brain Neoplasms | 18 | 2023 | 979 | 0.710 |
Why?
|
Smoking | 19 | 2019 | 1468 | 0.700 |
Why?
|
Retirement | 1 | 2020 | 27 | 0.680 |
Why?
|
Treatment Outcome | 41 | 2023 | 9165 | 0.670 |
Why?
|
Pathologists | 1 | 2019 | 15 | 0.660 |
Why?
|
Antigens, Neoplasm | 13 | 2009 | 224 | 0.630 |
Why?
|
Tubulin Modulators | 1 | 2018 | 9 | 0.620 |
Why?
|
T-Lymphocytes | 54 | 2020 | 1754 | 0.610 |
Why?
|
Furans | 1 | 2018 | 22 | 0.610 |
Why?
|
Ketones | 1 | 2018 | 44 | 0.600 |
Why?
|
Randomized Controlled Trials as Topic | 20 | 2018 | 1215 | 0.600 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 36 | 0.570 |
Why?
|
Sputum | 10 | 2019 | 291 | 0.560 |
Why?
|
Aged, 80 and over | 33 | 2019 | 6437 | 0.560 |
Why?
|
Aurora Kinase B | 1 | 2016 | 7 | 0.560 |
Why?
|
Thymidylate Synthase | 4 | 2005 | 11 | 0.550 |
Why?
|
Proto-Oncogene Proteins c-met | 6 | 2020 | 67 | 0.550 |
Why?
|
Sulindac | 5 | 2007 | 17 | 0.550 |
Why?
|
Pneumonectomy | 3 | 2015 | 126 | 0.540 |
Why?
|
Interferon Type I | 12 | 1995 | 129 | 0.530 |
Why?
|
Awards and Prizes | 1 | 2016 | 56 | 0.530 |
Why?
|
Medical Oncology | 5 | 2003 | 230 | 0.530 |
Why?
|
Neoplasm Proteins | 5 | 2009 | 388 | 0.530 |
Why?
|
Organophosphates | 1 | 2016 | 90 | 0.520 |
Why?
|
Gene Rearrangement | 8 | 2018 | 135 | 0.520 |
Why?
|
Adult | 119 | 2023 | 30813 | 0.520 |
Why?
|
Cell Line, Tumor | 18 | 2019 | 2749 | 0.510 |
Why?
|
Dose-Response Relationship, Drug | 21 | 2016 | 1868 | 0.490 |
Why?
|
Genomics | 3 | 2020 | 640 | 0.480 |
Why?
|
Neoplasms | 10 | 2010 | 2111 | 0.470 |
Why?
|
Chemoprevention | 5 | 2019 | 88 | 0.470 |
Why?
|
Cell Cycle | 11 | 2015 | 546 | 0.470 |
Why?
|
Esophagitis | 3 | 2012 | 65 | 0.450 |
Why?
|
Cadherins | 6 | 2012 | 175 | 0.450 |
Why?
|
Genes, erbB-1 | 6 | 2015 | 18 | 0.440 |
Why?
|
Precancerous Conditions | 6 | 2018 | 156 | 0.440 |
Why?
|
Disease Progression | 14 | 2022 | 2424 | 0.430 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2014 | 175 | 0.420 |
Why?
|
Mice, Nude | 18 | 2017 | 639 | 0.410 |
Why?
|
Melanoma | 5 | 2022 | 649 | 0.400 |
Why?
|
Genes, erbB-2 | 7 | 2017 | 26 | 0.400 |
Why?
|
Disease-Free Survival | 11 | 2018 | 621 | 0.400 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2004 | 312 | 0.390 |
Why?
|
Neuropeptides | 6 | 1998 | 65 | 0.390 |
Why?
|
Pyridines | 6 | 2013 | 425 | 0.390 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 9 | 2019 | 228 | 0.390 |
Why?
|
Drug Administration Schedule | 18 | 2011 | 724 | 0.390 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 361 | 0.380 |
Why?
|
Cell Division | 22 | 2007 | 760 | 0.380 |
Why?
|
Bronchi | 7 | 2018 | 253 | 0.380 |
Why?
|
Neoplasm Metastasis | 15 | 2019 | 526 | 0.370 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2010 | 40 | 0.370 |
Why?
|
Esophagus | 1 | 2012 | 224 | 0.370 |
Why?
|
Head and Neck Neoplasms | 4 | 2009 | 425 | 0.370 |
Why?
|
Acrylamides | 2 | 2022 | 43 | 0.370 |
Why?
|
Global Health | 1 | 2012 | 292 | 0.360 |
Why?
|
Ribonucleotide Reductases | 3 | 2004 | 21 | 0.350 |
Why?
|
Time Factors | 32 | 2018 | 6186 | 0.350 |
Why?
|
Animals | 66 | 2019 | 32119 | 0.350 |
Why?
|
Early Detection of Cancer | 6 | 2021 | 340 | 0.350 |
Why?
|
Signal Transduction | 17 | 2017 | 4525 | 0.340 |
Why?
|
Drug Screening Assays, Antitumor | 9 | 2009 | 180 | 0.340 |
Why?
|
Cell Proliferation | 9 | 2018 | 2196 | 0.340 |
Why?
|
Fever | 5 | 2001 | 280 | 0.340 |
Why?
|
Genotype | 2 | 2014 | 1843 | 0.340 |
Why?
|
Predictive Value of Tests | 12 | 2014 | 1817 | 0.340 |
Why?
|
Drug Delivery Systems | 2 | 2010 | 301 | 0.340 |
Why?
|
Phosphorylation | 6 | 2016 | 1560 | 0.330 |
Why?
|
Drug Monitoring | 1 | 2010 | 184 | 0.330 |
Why?
|
B7-H1 Antigen | 2 | 2022 | 138 | 0.330 |
Why?
|
Calcium | 6 | 2002 | 1102 | 0.330 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 3 | 2009 | 104 | 0.320 |
Why?
|
Salvage Therapy | 2 | 2007 | 128 | 0.320 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2019 | 703 | 0.320 |
Why?
|
Pyrazoles | 5 | 2013 | 362 | 0.320 |
Why?
|
Drug Therapy, Combination | 27 | 2002 | 961 | 0.310 |
Why?
|
Biomarkers | 4 | 2023 | 3473 | 0.310 |
Why?
|
Lymphoma, Non-Hodgkin | 6 | 2001 | 72 | 0.310 |
Why?
|
Flow Cytometry | 14 | 2006 | 1058 | 0.300 |
Why?
|
Mass Screening | 5 | 2020 | 1023 | 0.300 |
Why?
|
Cancer Vaccines | 1 | 2009 | 137 | 0.300 |
Why?
|
Meta-Analysis as Topic | 6 | 2017 | 163 | 0.300 |
Why?
|
Mesothelioma | 3 | 2004 | 31 | 0.290 |
Why?
|
Neoplasms, Experimental | 4 | 2002 | 153 | 0.290 |
Why?
|
Radiation-Sensitizing Agents | 2 | 1997 | 38 | 0.290 |
Why?
|
Leukemia | 16 | 2018 | 207 | 0.290 |
Why?
|
Receptors, KIR | 2 | 2018 | 89 | 0.280 |
Why?
|
Camptothecin | 5 | 2017 | 97 | 0.280 |
Why?
|
ras Proteins | 7 | 2014 | 137 | 0.280 |
Why?
|
Mice | 32 | 2019 | 15072 | 0.280 |
Why?
|
Protease Inhibitors | 2 | 2004 | 102 | 0.280 |
Why?
|
Oligopeptides | 4 | 2005 | 248 | 0.280 |
Why?
|
Interferons | 7 | 1995 | 152 | 0.280 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2023 | 332 | 0.270 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2018 | 178 | 0.270 |
Why?
|
Lung | 14 | 2023 | 3684 | 0.270 |
Why?
|
Bradykinin Receptor Antagonists | 2 | 2002 | 4 | 0.260 |
Why?
|
Proto-Oncogene Proteins B-raf | 5 | 2015 | 190 | 0.260 |
Why?
|
Carcinoma in Situ | 4 | 2019 | 44 | 0.260 |
Why?
|
Recombinant Proteins | 14 | 1998 | 1243 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2017 | 862 | 0.260 |
Why?
|
Thrombocytopenia | 7 | 2000 | 175 | 0.250 |
Why?
|
Apoptosis | 9 | 2018 | 2377 | 0.250 |
Why?
|
Biomedical Research | 3 | 2010 | 590 | 0.250 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 2002 | 72 | 0.250 |
Why?
|
Genes, ras | 5 | 2015 | 91 | 0.250 |
Why?
|
Antigens, Surface | 10 | 1988 | 151 | 0.250 |
Why?
|
Gene Expression Profiling | 8 | 2016 | 1547 | 0.240 |
Why?
|
Tankyrases | 2 | 2016 | 12 | 0.240 |
Why?
|
Liver Neoplasms | 7 | 2015 | 521 | 0.240 |
Why?
|
Indium Radioisotopes | 5 | 1991 | 24 | 0.240 |
Why?
|
Radiotherapy Dosage | 13 | 2007 | 246 | 0.240 |
Why?
|
Neovascularization, Pathologic | 7 | 2015 | 283 | 0.240 |
Why?
|
Boronic Acids | 1 | 2004 | 33 | 0.240 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 424 | 0.240 |
Why?
|
Committee Membership | 1 | 2003 | 2 | 0.230 |
Why?
|
Leukemia, Lymphoid | 7 | 1987 | 27 | 0.230 |
Why?
|
Volatile Organic Compounds | 3 | 2013 | 54 | 0.230 |
Why?
|
Pyrazines | 1 | 2004 | 70 | 0.230 |
Why?
|
Organophosphorus Compounds | 1 | 2004 | 73 | 0.230 |
Why?
|
Transplantation, Heterologous | 9 | 2006 | 188 | 0.230 |
Why?
|
Organizational Objectives | 1 | 2003 | 71 | 0.230 |
Why?
|
United States | 21 | 2020 | 12339 | 0.220 |
Why?
|
Follow-Up Studies | 18 | 2019 | 4446 | 0.220 |
Why?
|
Anticarcinogenic Agents | 1 | 2004 | 67 | 0.220 |
Why?
|
Anti-Bacterial Agents | 23 | 2001 | 1486 | 0.220 |
Why?
|
Delivery of Health Care | 1 | 2010 | 847 | 0.220 |
Why?
|
Oncogene Addiction | 1 | 2023 | 5 | 0.220 |
Why?
|
HTLV-I Infections | 2 | 1996 | 21 | 0.220 |
Why?
|
Neoplasm Transplantation | 11 | 2004 | 235 | 0.220 |
Why?
|
Retrospective Studies | 17 | 2019 | 12615 | 0.210 |
Why?
|
Receptor, ErbB-3 | 3 | 2009 | 42 | 0.210 |
Why?
|
Penicillins | 22 | 1969 | 52 | 0.210 |
Why?
|
Cluster Analysis | 4 | 2016 | 466 | 0.210 |
Why?
|
Iodine Radioisotopes | 5 | 1992 | 125 | 0.210 |
Why?
|
Doxorubicin | 21 | 2002 | 290 | 0.210 |
Why?
|
Organoplatinum Compounds | 3 | 2006 | 40 | 0.210 |
Why?
|
Growth Substances | 4 | 2000 | 136 | 0.210 |
Why?
|
Artificial Intelligence | 1 | 2023 | 146 | 0.210 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2002 | 34 | 0.210 |
Why?
|
Biopsy | 12 | 2023 | 1056 | 0.200 |
Why?
|
Airway Obstruction | 2 | 2003 | 170 | 0.200 |
Why?
|
Carcinoma, Bronchogenic | 10 | 1984 | 17 | 0.200 |
Why?
|
Aniline Compounds | 1 | 2022 | 73 | 0.200 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2022 | 54 | 0.200 |
Why?
|
Roxithromycin | 1 | 2001 | 1 | 0.200 |
Why?
|
Iloprost | 2 | 2012 | 46 | 0.200 |
Why?
|
Quality of Life | 5 | 2022 | 2391 | 0.200 |
Why?
|
Research Design | 7 | 2008 | 947 | 0.200 |
Why?
|
DNA, Neoplasm | 8 | 2013 | 156 | 0.200 |
Why?
|
Biological Products | 2 | 2023 | 172 | 0.200 |
Why?
|
Prospective Studies | 15 | 2023 | 6266 | 0.190 |
Why?
|
Neprilysin | 2 | 1998 | 47 | 0.190 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2017 | 16 | 0.190 |
Why?
|
Cell Cycle Checkpoints | 2 | 2018 | 84 | 0.190 |
Why?
|
Biomarkers, Pharmacological | 2 | 2019 | 26 | 0.190 |
Why?
|
Diarrhea | 1 | 2022 | 173 | 0.190 |
Why?
|
Cell Line | 24 | 2000 | 2655 | 0.190 |
Why?
|
Pleural Neoplasms | 2 | 2016 | 18 | 0.190 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2014 | 138 | 0.190 |
Why?
|
Antibiotic Prophylaxis | 1 | 2001 | 96 | 0.180 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2022 | 193 | 0.180 |
Why?
|
Societies, Medical | 2 | 2003 | 690 | 0.180 |
Why?
|
DNA Copy Number Variations | 2 | 2018 | 157 | 0.180 |
Why?
|
Patient Participation | 1 | 2003 | 362 | 0.180 |
Why?
|
Ki-67 Antigen | 4 | 2015 | 104 | 0.180 |
Why?
|
Oncogenes | 4 | 2016 | 104 | 0.180 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 4 | 2012 | 19 | 0.180 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2022 | 197 | 0.170 |
Why?
|
GTP Phosphohydrolases | 3 | 2015 | 66 | 0.170 |
Why?
|
Carcinoma, Large Cell | 4 | 2012 | 14 | 0.170 |
Why?
|
Vaping | 1 | 2020 | 46 | 0.170 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 83 | 0.170 |
Why?
|
Lymph Nodes | 17 | 1991 | 422 | 0.170 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2012 | 198 | 0.170 |
Why?
|
Epidermal Growth Factor | 4 | 2013 | 161 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 6 | 2016 | 819 | 0.170 |
Why?
|
Aminoquinolines | 1 | 2019 | 20 | 0.170 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2020 | 74 | 0.170 |
Why?
|
Breast Neoplasms | 8 | 2018 | 1870 | 0.160 |
Why?
|
Bronchoscopy | 9 | 2019 | 245 | 0.160 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 1403 | 0.160 |
Why?
|
Young Adult | 10 | 2020 | 10515 | 0.160 |
Why?
|
Friends | 1 | 2019 | 47 | 0.160 |
Why?
|
Structure-Activity Relationship | 6 | 2018 | 510 | 0.160 |
Why?
|
Homeodomain Proteins | 3 | 2010 | 465 | 0.160 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2004 | 182 | 0.160 |
Why?
|
History, 21st Century | 1 | 2019 | 164 | 0.160 |
Why?
|
Gene Expression | 6 | 2008 | 1442 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 3 | 2011 | 2209 | 0.160 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2004 | 58 | 0.160 |
Why?
|
Wasting Syndrome | 1 | 1998 | 11 | 0.160 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 2 | 1996 | 13 | 0.160 |
Why?
|
Receptor, IGF Type 1 | 2 | 2010 | 58 | 0.160 |
Why?
|
Caspase 3 | 2 | 2018 | 237 | 0.160 |
Why?
|
Interferon-alpha | 4 | 1995 | 187 | 0.150 |
Why?
|
Tumor Escape | 1 | 2018 | 35 | 0.150 |
Why?
|
Forecasting | 4 | 2003 | 332 | 0.150 |
Why?
|
Proto-Oncogenes | 2 | 2014 | 26 | 0.150 |
Why?
|
Lung Injury | 1 | 2020 | 201 | 0.150 |
Why?
|
Smoking Cessation | 3 | 2019 | 378 | 0.150 |
Why?
|
CpG Islands | 1 | 2018 | 123 | 0.150 |
Why?
|
Multiple Myeloma | 5 | 1997 | 93 | 0.150 |
Why?
|
Folic Acid | 4 | 2002 | 159 | 0.150 |
Why?
|
Cranial Irradiation | 2 | 1995 | 66 | 0.150 |
Why?
|
Lung Diseases | 6 | 2015 | 710 | 0.150 |
Why?
|
Palliative Care | 6 | 2003 | 643 | 0.150 |
Why?
|
Age Factors | 6 | 2016 | 2915 | 0.150 |
Why?
|
Cyclophosphamide | 19 | 2001 | 218 | 0.150 |
Why?
|
Genetic Association Studies | 2 | 2017 | 351 | 0.150 |
Why?
|
Vitamin B 12 | 3 | 2002 | 115 | 0.150 |
Why?
|
Clinical Protocols | 1 | 2019 | 233 | 0.150 |
Why?
|
Mutagenesis, Insertional | 1 | 2017 | 60 | 0.150 |
Why?
|
Bone Marrow | 10 | 1992 | 248 | 0.150 |
Why?
|
Proportional Hazards Models | 6 | 2016 | 1088 | 0.150 |
Why?
|
HLA Antigens | 4 | 1988 | 222 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 448 | 0.140 |
Why?
|
Receptors, KIR2DL3 | 1 | 2016 | 8 | 0.140 |
Why?
|
Receptors, KIR2DL4 | 1 | 2016 | 3 | 0.140 |
Why?
|
Receptors, KIR2DL1 | 1 | 2016 | 17 | 0.140 |
Why?
|
Receptors, KIR3DL1 | 1 | 2016 | 15 | 0.140 |
Why?
|
Interleukin-2 | 3 | 1995 | 414 | 0.140 |
Why?
|
Patients | 1 | 2018 | 164 | 0.140 |
Why?
|
Polyploidy | 1 | 2016 | 16 | 0.140 |
Why?
|
Empathy | 2 | 2009 | 141 | 0.140 |
Why?
|
DNA Mutational Analysis | 6 | 2017 | 378 | 0.140 |
Why?
|
Computational Biology | 2 | 2018 | 528 | 0.140 |
Why?
|
Chemoradiotherapy | 1 | 2018 | 187 | 0.140 |
Why?
|
RNA, Messenger | 7 | 2014 | 2581 | 0.140 |
Why?
|
Genes, myc | 1 | 2016 | 47 | 0.140 |
Why?
|
Bone Neoplasms | 4 | 2015 | 195 | 0.140 |
Why?
|
Genetic Therapy | 4 | 2015 | 267 | 0.140 |
Why?
|
Pleural Effusion, Malignant | 1 | 2016 | 14 | 0.140 |
Why?
|
Translocation, Genetic | 1 | 2016 | 94 | 0.140 |
Why?
|
Drug Evaluation | 14 | 1992 | 79 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 107 | 0.130 |
Why?
|
Disease Models, Animal | 5 | 2016 | 3583 | 0.130 |
Why?
|
Lymphoma, AIDS-Related | 1 | 1996 | 13 | 0.130 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 1996 | 23 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2016 | 84 | 0.130 |
Why?
|
Cohort Studies | 9 | 2019 | 4961 | 0.130 |
Why?
|
Dimerization | 3 | 2002 | 177 | 0.130 |
Why?
|
Peritoneal Neoplasms | 1 | 2016 | 54 | 0.130 |
Why?
|
Membrane Proteins | 3 | 2015 | 1033 | 0.130 |
Why?
|
Molecular Biology | 1 | 2016 | 56 | 0.130 |
Why?
|
Radiosurgery | 2 | 2014 | 298 | 0.130 |
Why?
|
Sex Factors | 6 | 2015 | 1743 | 0.130 |
Why?
|
Tumor Burden | 1 | 2016 | 261 | 0.130 |
Why?
|
Nerve Tissue Proteins | 1 | 1999 | 538 | 0.130 |
Why?
|
Antibodies, Viral | 11 | 2022 | 520 | 0.130 |
Why?
|
DNA Methylation | 2 | 2018 | 498 | 0.130 |
Why?
|
Remission Induction | 7 | 2019 | 240 | 0.130 |
Why?
|
Ifosfamide | 4 | 2008 | 32 | 0.130 |
Why?
|
Prevalence | 4 | 2023 | 2271 | 0.120 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2001 | 70 | 0.120 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 139 | 0.120 |
Why?
|
Patient-Specific Modeling | 1 | 2014 | 37 | 0.120 |
Why?
|
Bronchopulmonary Dysplasia | 1 | 2019 | 330 | 0.120 |
Why?
|
Biosensing Techniques | 2 | 2013 | 102 | 0.120 |
Why?
|
Up-Regulation | 3 | 2002 | 824 | 0.120 |
Why?
|
HIV | 1 | 1996 | 209 | 0.120 |
Why?
|
Amino Acid Sequence | 6 | 1999 | 2000 | 0.120 |
Why?
|
Administration, Oral | 5 | 2012 | 731 | 0.120 |
Why?
|
Transcription Factors | 3 | 2010 | 1530 | 0.120 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2015 | 81 | 0.120 |
Why?
|
Lymph Node Excision | 1 | 2015 | 140 | 0.120 |
Why?
|
Genetic Testing | 2 | 2011 | 385 | 0.120 |
Why?
|
Correction of Hearing Impairment | 1 | 2014 | 12 | 0.120 |
Why?
|
Drug Synergism | 4 | 2016 | 316 | 0.120 |
Why?
|
Tomography, Spiral Computed | 1 | 2013 | 24 | 0.120 |
Why?
|
Attitude to Computers | 1 | 2014 | 27 | 0.120 |
Why?
|
Activities of Daily Living | 1 | 2016 | 352 | 0.120 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 49 | 0.120 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2014 | 45 | 0.110 |
Why?
|
Persons With Hearing Impairments | 1 | 2014 | 21 | 0.110 |
Why?
|
PUVA Therapy | 3 | 1990 | 5 | 0.110 |
Why?
|
Interferon-gamma | 3 | 1995 | 731 | 0.110 |
Why?
|
Physicians | 2 | 2019 | 774 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 3 | 2013 | 78 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 5 | 2015 | 399 | 0.110 |
Why?
|
Retroviridae | 9 | 1983 | 90 | 0.110 |
Why?
|
Sequence Analysis, DNA | 2 | 2014 | 733 | 0.110 |
Why?
|
Deltaretrovirus Infections | 3 | 1988 | 6 | 0.110 |
Why?
|
Immunoenzyme Techniques | 4 | 2014 | 193 | 0.110 |
Why?
|
Software | 1 | 2017 | 531 | 0.110 |
Why?
|
Wnt Proteins | 2 | 2012 | 135 | 0.110 |
Why?
|
Hearing Aids | 1 | 2014 | 68 | 0.110 |
Why?
|
Hypogonadism | 1 | 2013 | 74 | 0.110 |
Why?
|
DNA | 6 | 1983 | 1358 | 0.110 |
Why?
|
Hyperplasia | 2 | 2011 | 166 | 0.100 |
Why?
|
Risk Factors | 9 | 2019 | 8714 | 0.100 |
Why?
|
Radioimmunotherapy | 1 | 1992 | 10 | 0.100 |
Why?
|
Risk Assessment | 5 | 2010 | 3004 | 0.100 |
Why?
|
Prostatic Neoplasms | 5 | 2018 | 927 | 0.100 |
Why?
|
Neurosecretory Systems | 2 | 2017 | 32 | 0.100 |
Why?
|
Genetic Variation | 1 | 2017 | 891 | 0.100 |
Why?
|
Androgens | 1 | 2013 | 165 | 0.100 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 934 | 0.100 |
Why?
|
Histones | 1 | 2016 | 539 | 0.100 |
Why?
|
Benzamides | 1 | 2012 | 169 | 0.100 |
Why?
|
Meningeal Neoplasms | 4 | 1986 | 87 | 0.100 |
Why?
|
Patient Selection | 6 | 2008 | 656 | 0.100 |
Why?
|
Molecular Sequence Data | 6 | 1999 | 2793 | 0.100 |
Why?
|
Cognition | 2 | 2009 | 982 | 0.100 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2002 | 47 | 0.100 |
Why?
|
Cetuximab | 3 | 2008 | 90 | 0.100 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2011 | 53 | 0.090 |
Why?
|
Deltaretrovirus | 6 | 1986 | 12 | 0.090 |
Why?
|
Transcriptome | 1 | 2016 | 741 | 0.090 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2015 | 76 | 0.090 |
Why?
|
MAP Kinase Kinase 1 | 3 | 2015 | 66 | 0.090 |
Why?
|
Antibiotics, Antitubercular | 11 | 1961 | 35 | 0.090 |
Why?
|
Antibody Formation | 2 | 2022 | 273 | 0.090 |
Why?
|
Gold | 1 | 2011 | 105 | 0.090 |
Why?
|
Hearing Loss | 1 | 2014 | 184 | 0.090 |
Why?
|
Zinc Finger E-box-Binding Homeobox 1 | 2 | 2010 | 23 | 0.090 |
Why?
|
Molecular Structure | 2 | 2005 | 447 | 0.090 |
Why?
|
Isoenzymes | 2 | 2004 | 286 | 0.090 |
Why?
|
Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
|
Radionuclide Imaging | 13 | 1991 | 121 | 0.090 |
Why?
|
Mucins | 1 | 1990 | 62 | 0.090 |
Why?
|
Dermatologic Agents | 11 | 1961 | 57 | 0.090 |
Why?
|
Tuberculosis | 19 | 1970 | 243 | 0.090 |
Why?
|
Testosterone | 1 | 2013 | 336 | 0.090 |
Why?
|
Indium | 5 | 1987 | 10 | 0.090 |
Why?
|
Staphylococcal Infections | 7 | 1981 | 338 | 0.090 |
Why?
|
Placebos | 3 | 2019 | 198 | 0.090 |
Why?
|
Catheter Ablation | 1 | 2012 | 280 | 0.090 |
Why?
|
Lymphoma, B-Cell | 1 | 2010 | 85 | 0.090 |
Why?
|
Random Allocation | 7 | 2017 | 338 | 0.080 |
Why?
|
Tocopherols | 1 | 2009 | 19 | 0.080 |
Why?
|
Expressed Emotion | 1 | 2009 | 18 | 0.080 |
Why?
|
Isotretinoin | 1 | 2009 | 22 | 0.080 |
Why?
|
Tumor Virus Infections | 3 | 1984 | 41 | 0.080 |
Why?
|
Antibodies, Neoplasm | 4 | 2001 | 29 | 0.080 |
Why?
|
Central Nervous System Diseases | 2 | 1983 | 62 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2011 | 308 | 0.080 |
Why?
|
Blotting, Western | 6 | 2014 | 1153 | 0.080 |
Why?
|
Kanamycin | 6 | 1970 | 8 | 0.080 |
Why?
|
MicroRNAs | 2 | 2012 | 610 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2002 | 277 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2023 | 2814 | 0.080 |
Why?
|
Spinal Cord Neoplasms | 4 | 1986 | 40 | 0.080 |
Why?
|
Fluorenes | 1 | 2009 | 38 | 0.080 |
Why?
|
Rats | 6 | 2005 | 5035 | 0.080 |
Why?
|
Vincristine | 13 | 1989 | 96 | 0.080 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2008 | 63 | 0.080 |
Why?
|
Cell Survival | 5 | 2013 | 1026 | 0.080 |
Why?
|
Podophyllotoxin | 3 | 2003 | 7 | 0.080 |
Why?
|
Aneuploidy | 5 | 2010 | 86 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2007 | 1115 | 0.080 |
Why?
|
Lymphatic Metastasis | 6 | 2020 | 275 | 0.080 |
Why?
|
Rats, Nude | 4 | 2003 | 27 | 0.080 |
Why?
|
Amides | 1 | 2009 | 89 | 0.080 |
Why?
|
Topotecan | 2 | 2017 | 14 | 0.080 |
Why?
|
National Institutes of Health (U.S.) | 4 | 1996 | 106 | 0.080 |
Why?
|
Mice, Inbred BALB C | 4 | 2004 | 1165 | 0.080 |
Why?
|
Multigene Family | 2 | 2006 | 196 | 0.080 |
Why?
|
Social Perception | 1 | 2009 | 97 | 0.080 |
Why?
|
Antisocial Personality Disorder | 1 | 2009 | 159 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 682 | 0.080 |
Why?
|
Sample Size | 1 | 2008 | 119 | 0.080 |
Why?
|
Nanoparticles | 1 | 2011 | 318 | 0.080 |
Why?
|
Kinetics | 8 | 1991 | 1560 | 0.080 |
Why?
|
Radiography | 8 | 2002 | 827 | 0.080 |
Why?
|
Inflammation | 1 | 2018 | 2503 | 0.080 |
Why?
|
Epithelial Cells | 4 | 2007 | 965 | 0.070 |
Why?
|
Chromosome Aberrations | 6 | 1993 | 136 | 0.070 |
Why?
|
Polymorphism, Genetic | 1 | 2011 | 632 | 0.070 |
Why?
|
Multivariate Analysis | 5 | 2016 | 1444 | 0.070 |
Why?
|
Exons | 2 | 2019 | 303 | 0.070 |
Why?
|
Models, Statistical | 1 | 1991 | 616 | 0.070 |
Why?
|
Incidence | 3 | 2018 | 2333 | 0.070 |
Why?
|
Bombesin | 3 | 1994 | 14 | 0.070 |
Why?
|
Immunoglobulins | 2 | 1985 | 148 | 0.070 |
Why?
|
Fibroblast Growth Factors | 1 | 2008 | 162 | 0.070 |
Why?
|
Receptors, Growth Factor | 2 | 1997 | 49 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 301 | 0.070 |
Why?
|
Epitopes | 3 | 1986 | 438 | 0.070 |
Why?
|
Psychological Tests | 1 | 2007 | 124 | 0.070 |
Why?
|
Databases, Genetic | 2 | 2018 | 200 | 0.070 |
Why?
|
Congresses as Topic | 3 | 2020 | 200 | 0.070 |
Why?
|
Bevacizumab | 1 | 2007 | 118 | 0.070 |
Why?
|
Cytokines | 4 | 1997 | 1857 | 0.070 |
Why?
|
Radioisotopes | 4 | 1987 | 34 | 0.070 |
Why?
|
Mesoderm | 1 | 2007 | 138 | 0.070 |
Why?
|
Radioimmunoassay | 3 | 1986 | 163 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1987 | 58 | 0.070 |
Why?
|
Tegafur | 1 | 2005 | 3 | 0.070 |
Why?
|
Immunologic Factors | 3 | 1996 | 219 | 0.070 |
Why?
|
Aging | 2 | 2014 | 1640 | 0.070 |
Why?
|
Platinum Compounds | 1 | 2005 | 11 | 0.070 |
Why?
|
Adolescent | 10 | 2020 | 17949 | 0.070 |
Why?
|
Uracil | 1 | 2005 | 31 | 0.070 |
Why?
|
Teniposide | 2 | 2003 | 3 | 0.070 |
Why?
|
Receptors, Cell Surface | 2 | 2001 | 358 | 0.070 |
Why?
|
In Situ Nick-End Labeling | 2 | 2003 | 119 | 0.060 |
Why?
|
Area Under Curve | 2 | 2005 | 277 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2014 | 1193 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 504 | 0.060 |
Why?
|
Affect | 1 | 2007 | 244 | 0.060 |
Why?
|
beta 2-Microglobulin | 1 | 1985 | 45 | 0.060 |
Why?
|
Resting Phase, Cell Cycle | 1 | 2005 | 15 | 0.060 |
Why?
|
Polymerase Chain Reaction | 2 | 2006 | 1001 | 0.060 |
Why?
|
PTEN Phosphohydrolase | 1 | 2006 | 141 | 0.060 |
Why?
|
Anti-Infective Agents | 4 | 2001 | 225 | 0.060 |
Why?
|
Drug Resistance | 5 | 2006 | 162 | 0.060 |
Why?
|
Matrix Metalloproteinase Inhibitors | 2 | 2005 | 13 | 0.060 |
Why?
|
G1 Phase | 1 | 2005 | 68 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 445 | 0.060 |
Why?
|
Binding Sites, Antibody | 1 | 1984 | 36 | 0.060 |
Why?
|
Radiation, Ionizing | 1 | 2005 | 73 | 0.060 |
Why?
|
Selenium | 2 | 2004 | 31 | 0.060 |
Why?
|
Injections, Subcutaneous | 3 | 2002 | 137 | 0.060 |
Why?
|
Trastuzumab | 2 | 2002 | 89 | 0.060 |
Why?
|
Regression Analysis | 3 | 2003 | 961 | 0.060 |
Why?
|
Drug Therapy | 5 | 1983 | 78 | 0.060 |
Why?
|
Surveys and Questionnaires | 4 | 2014 | 4670 | 0.060 |
Why?
|
Data Collection | 1 | 2007 | 636 | 0.060 |
Why?
|
Bortezomib | 1 | 2004 | 41 | 0.060 |
Why?
|
Animal Welfare | 1 | 2004 | 14 | 0.060 |
Why?
|
Biological Therapy | 1 | 2004 | 26 | 0.060 |
Why?
|
Radiotherapy | 6 | 1994 | 177 | 0.060 |
Why?
|
Retroviridae Infections | 4 | 1985 | 45 | 0.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 146 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 1976 | 93 | 0.060 |
Why?
|
Karyotyping | 6 | 1996 | 102 | 0.060 |
Why?
|
Retinoids | 1 | 2004 | 31 | 0.060 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 59 | 0.060 |
Why?
|
Planning Techniques | 1 | 2003 | 13 | 0.060 |
Why?
|
Vaccination | 2 | 2022 | 1205 | 0.060 |
Why?
|
Decision Making, Organizational | 1 | 2003 | 25 | 0.060 |
Why?
|
Immunologic Tests | 1 | 2023 | 16 | 0.060 |
Why?
|
Nucleocapsid | 1 | 2023 | 17 | 0.060 |
Why?
|
Lymphocytes | 1 | 1985 | 342 | 0.060 |
Why?
|
Necrosis | 1 | 2004 | 211 | 0.060 |
Why?
|
Biotechnology | 1 | 2004 | 46 | 0.060 |
Why?
|
Immunotoxins | 2 | 1995 | 33 | 0.060 |
Why?
|
Vitamin E | 1 | 2004 | 111 | 0.060 |
Why?
|
Transfection | 1 | 2006 | 866 | 0.060 |
Why?
|
Methotrexate | 11 | 1986 | 228 | 0.060 |
Why?
|
Nervous System Neoplasms | 1 | 1983 | 2 | 0.060 |
Why?
|
Pilot Projects | 3 | 2012 | 1374 | 0.060 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 165 | 0.050 |
Why?
|
Meninges | 4 | 1982 | 29 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 1988 | 376 | 0.050 |
Why?
|
Radiation Tolerance | 1 | 2004 | 92 | 0.050 |
Why?
|
Parents | 2 | 2009 | 1210 | 0.050 |
Why?
|
Pandemics | 2 | 2022 | 1333 | 0.050 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2017 | 168 | 0.050 |
Why?
|
Skin | 7 | 1987 | 668 | 0.050 |
Why?
|
Methylmalonic Acid | 1 | 2002 | 58 | 0.050 |
Why?
|
Proteome | 1 | 2006 | 344 | 0.050 |
Why?
|
Fruit | 1 | 2003 | 124 | 0.050 |
Why?
|
Stomach Neoplasms | 2 | 1982 | 66 | 0.050 |
Why?
|
Vegetables | 1 | 2003 | 128 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2002 | 791 | 0.050 |
Why?
|
Farnesyltranstransferase | 1 | 2002 | 21 | 0.050 |
Why?
|
Metaplasia | 2 | 2018 | 54 | 0.050 |
Why?
|
Streptozocin | 3 | 1983 | 16 | 0.050 |
Why?
|
Autoradiography | 3 | 1981 | 71 | 0.050 |
Why?
|
Injections, Intralesional | 1 | 2002 | 32 | 0.050 |
Why?
|
Infusion Pumps | 1 | 2002 | 32 | 0.050 |
Why?
|
Tetrazolium Salts | 1 | 2002 | 18 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2007 | 754 | 0.050 |
Why?
|
Injections, Intraperitoneal | 1 | 2002 | 104 | 0.050 |
Why?
|
Homocysteine | 1 | 2002 | 136 | 0.050 |
Why?
|
SEER Program | 1 | 2003 | 193 | 0.050 |
Why?
|
Peptides | 3 | 2001 | 862 | 0.050 |
Why?
|
Hypercalcemia | 4 | 1986 | 21 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2002 | 41 | 0.050 |
Why?
|
Dietary Supplements | 2 | 2004 | 460 | 0.050 |
Why?
|
Antigen-Antibody Complex | 4 | 1986 | 88 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2003 | 249 | 0.050 |
Why?
|
Metalloendopeptidases | 2 | 2002 | 55 | 0.050 |
Why?
|
Mechlorethamine | 3 | 1994 | 64 | 0.050 |
Why?
|
Mediastinal Neoplasms | 1 | 2002 | 32 | 0.050 |
Why?
|
Testis | 1 | 2002 | 134 | 0.050 |
Why?
|
Infusions, Intravenous | 3 | 2004 | 374 | 0.050 |
Why?
|
Ciprofloxacin | 1 | 2001 | 23 | 0.050 |
Why?
|
Thiazoles | 1 | 2002 | 112 | 0.050 |
Why?
|
Leukopenia | 5 | 1995 | 27 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2019 | 1665 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1985 | 630 | 0.050 |
Why?
|
HIV Infections | 1 | 1996 | 2469 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2017 | 310 | 0.050 |
Why?
|
Pedigree | 3 | 2000 | 474 | 0.050 |
Why?
|
Endpoint Determination | 1 | 2001 | 69 | 0.050 |
Why?
|
Kinins | 1 | 2001 | 3 | 0.050 |
Why?
|
Fluorescence | 1 | 2001 | 153 | 0.050 |
Why?
|
Neoplastic Cells, Circulating | 2 | 1984 | 59 | 0.050 |
Why?
|
Central Nervous System | 1 | 2023 | 239 | 0.050 |
Why?
|
Endothelium, Vascular | 2 | 2004 | 845 | 0.050 |
Why?
|
Leukemia, Plasma Cell | 1 | 1980 | 5 | 0.050 |
Why?
|
Paraproteinemias | 1 | 1980 | 4 | 0.050 |
Why?
|
Hypergammaglobulinemia | 1 | 1980 | 9 | 0.050 |
Why?
|
Cervical Vertebrae | 1 | 2002 | 104 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2015 | 1728 | 0.050 |
Why?
|
Plasmacytoma | 1 | 1980 | 10 | 0.050 |
Why?
|
Lymphoproliferative Disorders | 3 | 1988 | 46 | 0.050 |
Why?
|
Cell Count | 3 | 1996 | 304 | 0.050 |
Why?
|
Microtubules | 1 | 2003 | 238 | 0.050 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 44 | 0.050 |
Why?
|
Microscopy, Fluorescence | 1 | 2002 | 403 | 0.050 |
Why?
|
Receptors, Interleukin-2 | 2 | 1995 | 65 | 0.040 |
Why?
|
Receptors, Virus | 1 | 2020 | 76 | 0.040 |
Why?
|
Ploidies | 4 | 2003 | 17 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2020 | 353 | 0.040 |
Why?
|
Antioxidants | 1 | 2004 | 533 | 0.040 |
Why?
|
Algorithms | 3 | 2015 | 1493 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2000 | 78 | 0.040 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 445 | 0.040 |
Why?
|
Lipoxygenase Inhibitors | 1 | 1999 | 36 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2000 | 750 | 0.040 |
Why?
|
Observer Variation | 1 | 2020 | 299 | 0.040 |
Why?
|
ELAV Proteins | 1 | 1999 | 17 | 0.040 |
Why?
|
Sepsis | 3 | 1981 | 519 | 0.040 |
Why?
|
Gene Transfer Techniques | 2 | 1998 | 149 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2000 | 200 | 0.040 |
Why?
|
Carcinoembryonic Antigen | 1 | 1979 | 37 | 0.040 |
Why?
|
Stomach Diseases | 1 | 1979 | 19 | 0.040 |
Why?
|
Wounds, Nonpenetrating | 1 | 2002 | 228 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2013 | 617 | 0.040 |
Why?
|
Streptomycin | 8 | 1954 | 13 | 0.040 |
Why?
|
Light | 1 | 2001 | 334 | 0.040 |
Why?
|
Electrons | 4 | 1989 | 73 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2012 | 3056 | 0.040 |
Why?
|
Stomach | 1 | 1979 | 101 | 0.040 |
Why?
|
Spinal Cord Injuries | 1 | 2002 | 175 | 0.040 |
Why?
|
gamma Catenin | 1 | 2018 | 17 | 0.040 |
Why?
|
Desmoglein 3 | 1 | 2018 | 17 | 0.040 |
Why?
|
Antibodies | 3 | 1990 | 374 | 0.040 |
Why?
|
History, 20th Century | 2 | 1996 | 276 | 0.040 |
Why?
|
Administration, Topical | 2 | 1994 | 137 | 0.040 |
Why?
|
Carcinoma | 4 | 2001 | 200 | 0.040 |
Why?
|
Smokers | 1 | 2019 | 147 | 0.040 |
Why?
|
Postoperative Care | 1 | 2000 | 222 | 0.040 |
Why?
|
HIV Wasting Syndrome | 1 | 1998 | 4 | 0.040 |
Why?
|
Protein Kinase C | 1 | 2000 | 274 | 0.040 |
Why?
|
Skin Diseases | 2 | 1979 | 124 | 0.040 |
Why?
|
Models, Molecular | 2 | 2018 | 1391 | 0.040 |
Why?
|
Organoids | 1 | 2019 | 75 | 0.040 |
Why?
|
Pneumonia | 6 | 1968 | 576 | 0.040 |
Why?
|
Bronchial Diseases | 1 | 2018 | 38 | 0.040 |
Why?
|
Hematologic Diseases | 3 | 1995 | 57 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2012 | 546 | 0.040 |
Why?
|
Teaching | 1 | 2020 | 226 | 0.040 |
Why?
|
Gastrin-Releasing Peptide | 2 | 1996 | 6 | 0.040 |
Why?
|
Communicable Diseases | 4 | 1964 | 131 | 0.040 |
Why?
|
Tissue Distribution | 5 | 1990 | 324 | 0.040 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2017 | 3 | 0.040 |
Why?
|
Genes, p53 | 1 | 1998 | 62 | 0.040 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2017 | 17 | 0.040 |
Why?
|
Type C Phospholipases | 1 | 1998 | 66 | 0.040 |
Why?
|
Preoperative Care | 1 | 2000 | 317 | 0.040 |
Why?
|
North America | 1 | 1998 | 262 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 171 | 0.040 |
Why?
|
Web Browser | 1 | 2017 | 11 | 0.040 |
Why?
|
Drug Resistance, Multiple | 1 | 1997 | 19 | 0.040 |
Why?
|
Demecolcine | 1 | 1976 | 2 | 0.040 |
Why?
|
Receptors, Notch | 1 | 2017 | 85 | 0.040 |
Why?
|
B-Lymphocytes | 5 | 1986 | 770 | 0.040 |
Why?
|
Endocarditis, Subacute Bacterial | 3 | 1964 | 3 | 0.040 |
Why?
|
Mice, SCID | 1 | 2017 | 321 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2003 | 2437 | 0.040 |
Why?
|
Bronchial Neoplasms | 1 | 1996 | 14 | 0.040 |
Why?
|
Platinum | 1 | 2016 | 40 | 0.040 |
Why?
|
Risk | 5 | 2001 | 830 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2007 | 182 | 0.030 |
Why?
|
Tuberculosis, Ocular | 5 | 1954 | 5 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 1996 | 129 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2017 | 141 | 0.030 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2018 | 153 | 0.030 |
Why?
|
Diet | 1 | 2003 | 1075 | 0.030 |
Why?
|
Carcinogenesis | 1 | 2017 | 177 | 0.030 |
Why?
|
Mitogens | 4 | 1998 | 58 | 0.030 |
Why?
|
Endocarditis | 3 | 1964 | 32 | 0.030 |
Why?
|
RNA-Binding Proteins | 1 | 1999 | 365 | 0.030 |
Why?
|
Receptors, Cytokine | 1 | 1996 | 34 | 0.030 |
Why?
|
Comorbidity | 2 | 2016 | 1476 | 0.030 |
Why?
|
Drug Stability | 1 | 1996 | 152 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 221 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 407 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 562 | 0.030 |
Why?
|
Premedication | 1 | 1995 | 36 | 0.030 |
Why?
|
Analgesics, Non-Narcotic | 1 | 1997 | 117 | 0.030 |
Why?
|
Meningitis | 4 | 1974 | 74 | 0.030 |
Why?
|
Rabbits | 10 | 2005 | 754 | 0.030 |
Why?
|
Growth Inhibitors | 2 | 2002 | 45 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2003 | 2598 | 0.030 |
Why?
|
Hematopoiesis | 1 | 1976 | 175 | 0.030 |
Why?
|
Glioblastoma | 1 | 2018 | 251 | 0.030 |
Why?
|
Cross-Linking Reagents | 1 | 1996 | 182 | 0.030 |
Why?
|
Pathology, Molecular | 1 | 2015 | 26 | 0.030 |
Why?
|
GTP-Binding Proteins | 1 | 1996 | 142 | 0.030 |
Why?
|
Interferon-beta | 1 | 1995 | 80 | 0.030 |
Why?
|
Colorado | 2 | 2014 | 4122 | 0.030 |
Why?
|
Drug Tolerance | 1 | 1995 | 79 | 0.030 |
Why?
|
HLA-A Antigens | 2 | 1985 | 50 | 0.030 |
Why?
|
Guinea Pigs | 3 | 2005 | 148 | 0.030 |
Why?
|
Diphtheria Toxin | 1 | 1995 | 51 | 0.030 |
Why?
|
HLA-C Antigens | 2 | 1985 | 32 | 0.030 |
Why?
|
Bone Marrow Transplantation | 2 | 1986 | 241 | 0.030 |
Why?
|
Wnt Signaling Pathway | 1 | 2016 | 147 | 0.030 |
Why?
|
HLA-B Antigens | 2 | 1985 | 55 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 1996 | 101 | 0.030 |
Why?
|
Whole-Body Irradiation | 3 | 1991 | 72 | 0.030 |
Why?
|
Photopheresis | 1 | 1994 | 9 | 0.030 |
Why?
|
Antigens, Viral | 4 | 1984 | 174 | 0.030 |
Why?
|
Mitomycin | 2 | 1992 | 27 | 0.030 |
Why?
|
Glioma | 1 | 2018 | 296 | 0.030 |
Why?
|
Cholecystokinin | 1 | 1994 | 15 | 0.030 |
Why?
|
Proteins | 1 | 2000 | 922 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2015 | 91 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2018 | 555 | 0.030 |
Why?
|
Methoxsalen | 1 | 1994 | 4 | 0.030 |
Why?
|
Substance P | 1 | 1994 | 44 | 0.030 |
Why?
|
Ultraviolet Therapy | 1 | 1994 | 16 | 0.030 |
Why?
|
gamma-Globulins | 2 | 1965 | 18 | 0.030 |
Why?
|
Texas | 1 | 2014 | 187 | 0.030 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 1994 | 6 | 0.030 |
Why?
|
Contraindications | 1 | 1994 | 85 | 0.030 |
Why?
|
Military Medicine | 1 | 1996 | 93 | 0.030 |
Why?
|
Research | 2 | 1994 | 398 | 0.030 |
Why?
|
Pyridazines | 1 | 2014 | 46 | 0.030 |
Why?
|
Fibroblasts | 1 | 1998 | 838 | 0.030 |
Why?
|
Odds Ratio | 1 | 2016 | 970 | 0.030 |
Why?
|
Serum Albumin | 2 | 2013 | 135 | 0.030 |
Why?
|
Consensus | 1 | 2016 | 533 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2000 | 1319 | 0.030 |
Why?
|
Micrococcus | 3 | 1958 | 4 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 3 | 1992 | 33 | 0.030 |
Why?
|
Staphylococcus | 3 | 1970 | 69 | 0.030 |
Why?
|
Ileum | 2 | 2005 | 93 | 0.030 |
Why?
|
Safety | 1 | 1995 | 298 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 3086 | 0.030 |
Why?
|
Endoscopy | 1 | 2015 | 247 | 0.030 |
Why?
|
Urinary Tract Infections | 3 | 1970 | 136 | 0.030 |
Why?
|
Muscle Denervation | 1 | 1973 | 9 | 0.030 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2013 | 47 | 0.030 |
Why?
|
DNA Fingerprinting | 1 | 2013 | 27 | 0.030 |
Why?
|
Radiation Dosage | 2 | 1992 | 141 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 319 | 0.030 |
Why?
|
Maintenance Chemotherapy | 1 | 2013 | 22 | 0.030 |
Why?
|
In Vitro Techniques | 5 | 2002 | 1044 | 0.030 |
Why?
|
Auditory Perception | 1 | 2014 | 101 | 0.030 |
Why?
|
Imidazoles | 1 | 2014 | 215 | 0.030 |
Why?
|
Solid Phase Microextraction | 1 | 2012 | 6 | 0.030 |
Why?
|
Treatment Failure | 1 | 1994 | 333 | 0.030 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 1992 | 31 | 0.030 |
Why?
|
DNA Primers | 2 | 2009 | 513 | 0.030 |
Why?
|
Neuromuscular Junction | 1 | 1973 | 53 | 0.030 |
Why?
|
Chromosome Banding | 4 | 1996 | 21 | 0.030 |
Why?
|
Cooperative Behavior | 1 | 2015 | 390 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2013 | 86 | 0.030 |
Why?
|
Breath Tests | 1 | 2012 | 85 | 0.030 |
Why?
|
Luteinizing Hormone | 1 | 2013 | 169 | 0.030 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2012 | 127 | 0.030 |
Why?
|
Hearing | 1 | 2014 | 132 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 1995 | 616 | 0.030 |
Why?
|
International Cooperation | 2 | 2003 | 175 | 0.030 |
Why?
|
Bone Marrow Examination | 1 | 1992 | 7 | 0.030 |
Why?
|
Liver | 5 | 1987 | 1693 | 0.030 |
Why?
|
Adrenocorticotropic Hormone | 4 | 1954 | 148 | 0.030 |
Why?
|
Ionomycin | 1 | 1992 | 24 | 0.030 |
Why?
|
Species Specificity | 2 | 2005 | 555 | 0.030 |
Why?
|
Ricin | 1 | 1991 | 8 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 1 | 2013 | 214 | 0.030 |
Why?
|
Probability | 3 | 2009 | 297 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2013 | 137 | 0.030 |
Why?
|
Pyridones | 1 | 2013 | 123 | 0.030 |
Why?
|
Immunization, Passive | 2 | 2001 | 79 | 0.030 |
Why?
|
Equipment Design | 1 | 2014 | 516 | 0.030 |
Why?
|
Nanostructures | 1 | 2013 | 98 | 0.030 |
Why?
|
Chromosome Deletion | 2 | 1982 | 95 | 0.030 |
Why?
|
Ambulatory Care | 1 | 1995 | 480 | 0.020 |
Why?
|
Properdin | 2 | 1962 | 8 | 0.020 |
Why?
|
Radiometry | 1 | 1992 | 43 | 0.020 |
Why?
|
Logistic Models | 1 | 2016 | 1865 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 507 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2014 | 278 | 0.020 |
Why?
|
Tuberculosis, Pulmonary | 4 | 1959 | 112 | 0.020 |
Why?
|
Immunosorbent Techniques | 1 | 1991 | 17 | 0.020 |
Why?
|
Drug Hypersensitivity | 2 | 1970 | 86 | 0.020 |
Why?
|
Laboratories | 2 | 1963 | 95 | 0.020 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 1982 | 11 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2015 | 4449 | 0.020 |
Why?
|
Vimentin | 1 | 2011 | 58 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1990 | 221 | 0.020 |
Why?
|
Japan | 2 | 2009 | 89 | 0.020 |
Why?
|
Lomustine | 7 | 1986 | 14 | 0.020 |
Why?
|
Iceland | 1 | 2011 | 6 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1992 | 165 | 0.020 |
Why?
|
Perception | 1 | 2014 | 316 | 0.020 |
Why?
|
Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 12 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 686 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 794 | 0.020 |
Why?
|
Spain | 1 | 2011 | 36 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2013 | 296 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1991 | 54 | 0.020 |
Why?
|
Netherlands | 1 | 2011 | 65 | 0.020 |
Why?
|
Adsorption | 1 | 1991 | 127 | 0.020 |
Why?
|
Zinc Finger E-box Binding Homeobox 2 | 1 | 2010 | 5 | 0.020 |
Why?
|
Databases, Factual | 1 | 1996 | 1149 | 0.020 |
Why?
|
Motor Neurons | 1 | 1973 | 213 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 1994 | 261 | 0.020 |
Why?
|
Photochemotherapy | 2 | 1980 | 29 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2002 | 1358 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2010 | 49 | 0.020 |
Why?
|
Megakaryocytes | 3 | 1980 | 30 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 102 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1990 | 150 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 2 | 1980 | 12 | 0.020 |
Why?
|
Base Sequence | 2 | 2009 | 2120 | 0.020 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 2 | 1988 | 19 | 0.020 |
Why?
|
Clone Cells | 3 | 1985 | 247 | 0.020 |
Why?
|
Nervous System Diseases | 3 | 1985 | 253 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1994 | 703 | 0.020 |
Why?
|
Nicotinic Acids | 3 | 1954 | 6 | 0.020 |
Why?
|
Hemagglutination Tests | 2 | 1964 | 7 | 0.020 |
Why?
|
Mitosis | 3 | 1981 | 164 | 0.020 |
Why?
|
Niacin | 3 | 1954 | 19 | 0.020 |
Why?
|
Bacterial Infections | 2 | 2001 | 222 | 0.020 |
Why?
|
Down-Regulation | 1 | 1992 | 605 | 0.020 |
Why?
|
Calcitriol | 2 | 1986 | 53 | 0.020 |
Why?
|
Proteomics | 2 | 2007 | 854 | 0.020 |
Why?
|
Deafness | 1 | 1970 | 78 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2014 | 647 | 0.020 |
Why?
|
Diethylstilbestrol | 2 | 1986 | 8 | 0.020 |
Why?
|
Isoniazid | 3 | 1954 | 52 | 0.020 |
Why?
|
Personality Inventory | 1 | 2009 | 135 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 2010 | 107 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 1991 | 281 | 0.020 |
Why?
|
Infusions, Parenteral | 2 | 1986 | 38 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2009 | 154 | 0.020 |
Why?
|
Pulmonary Fibrosis | 2 | 1986 | 331 | 0.020 |
Why?
|
Ovary | 1 | 1990 | 190 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 389 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2002 | 2408 | 0.020 |
Why?
|
Histocytochemistry | 3 | 1983 | 78 | 0.020 |
Why?
|
Herpes Simplex | 2 | 1987 | 88 | 0.020 |
Why?
|
Tuberculosis, Meningeal | 4 | 1964 | 6 | 0.020 |
Why?
|
Immunophenotyping | 2 | 2001 | 273 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 390 | 0.020 |
Why?
|
Tetracycline | 2 | 1958 | 11 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 2 | 1987 | 399 | 0.020 |
Why?
|
Bone Marrow Cells | 3 | 1980 | 272 | 0.020 |
Why?
|
New South Wales | 1 | 2007 | 10 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2008 | 298 | 0.020 |
Why?
|
Rosette Formation | 2 | 1987 | 16 | 0.020 |
Why?
|
Queensland | 1 | 2007 | 40 | 0.020 |
Why?
|
Ampicillin | 2 | 1965 | 13 | 0.020 |
Why?
|
Protein Synthesis Inhibitors | 2 | 1958 | 44 | 0.020 |
Why?
|
Eye | 3 | 1954 | 101 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1987 | 21 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2010 | 369 | 0.020 |
Why?
|
Body Fluids | 2 | 1964 | 58 | 0.020 |
Why?
|
Remission, Spontaneous | 4 | 1980 | 37 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 1989 | 319 | 0.020 |
Why?
|
Hydrocortisone | 2 | 1981 | 272 | 0.020 |
Why?
|
Pneumonia, Pneumococcal | 2 | 1960 | 37 | 0.020 |
Why?
|
Procarbazine | 5 | 1986 | 8 | 0.020 |
Why?
|
Dyspnea | 2 | 1986 | 223 | 0.020 |
Why?
|
Genome, Human | 1 | 2009 | 374 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2007 | 181 | 0.020 |
Why?
|
California | 1 | 2008 | 369 | 0.020 |
Why?
|
Reference Values | 1 | 2008 | 745 | 0.020 |
Why?
|
Calcitonin | 1 | 1986 | 23 | 0.020 |
Why?
|
Nucleotidases | 2 | 1985 | 7 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 1986 | 92 | 0.020 |
Why?
|
Child | 4 | 2009 | 18550 | 0.020 |
Why?
|
Genome | 1 | 2009 | 266 | 0.020 |
Why?
|
Bacillus | 2 | 1957 | 14 | 0.020 |
Why?
|
Child, Preschool | 3 | 2007 | 9174 | 0.020 |
Why?
|
Phosphates | 2 | 1958 | 160 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2009 | 296 | 0.020 |
Why?
|
DNA Repair | 1 | 2008 | 192 | 0.020 |
Why?
|
Sulfadiazine | 1 | 1966 | 4 | 0.020 |
Why?
|
Nocardia Infections | 1 | 1966 | 7 | 0.020 |
Why?
|
Gram-Positive Bacteria | 2 | 1957 | 46 | 0.020 |
Why?
|
Immunoglobulin Idiotypes | 1 | 1986 | 19 | 0.020 |
Why?
|
Insecta | 2 | 1957 | 63 | 0.020 |
Why?
|
Radioisotope Dilution Technique | 1 | 1986 | 13 | 0.020 |
Why?
|
Antigen-Antibody Reactions | 1 | 1966 | 49 | 0.020 |
Why?
|
Farmer's Lung | 1 | 1965 | 3 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1986 | 82 | 0.020 |
Why?
|
Erythromycin | 2 | 1958 | 24 | 0.020 |
Why?
|
Mice, Inbred A | 1 | 2005 | 45 | 0.020 |
Why?
|
Databases, Nucleic Acid | 1 | 2005 | 32 | 0.020 |
Why?
|
Deoxyribonucleosides | 1 | 1985 | 2 | 0.020 |
Why?
|
Urea | 1 | 1966 | 69 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1986 | 129 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 1986 | 100 | 0.020 |
Why?
|
Peritonitis | 1 | 1966 | 76 | 0.020 |
Why?
|
DNA Damage | 1 | 2008 | 356 | 0.020 |
Why?
|
Cell Movement | 2 | 1981 | 868 | 0.020 |
Why?
|
Freezing | 1 | 1986 | 85 | 0.020 |
Why?
|
Mathematics | 1 | 1986 | 101 | 0.020 |
Why?
|
Mycoses | 1 | 1966 | 67 | 0.020 |
Why?
|
Blood | 1 | 1985 | 97 | 0.020 |
Why?
|
HLA-B35 Antigen | 1 | 1985 | 3 | 0.020 |
Why?
|
HLA-B8 Antigen | 1 | 1985 | 14 | 0.020 |
Why?
|
Enzymes | 1 | 2005 | 61 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2008 | 1226 | 0.020 |
Why?
|
Bleomycin | 2 | 1978 | 232 | 0.020 |
Why?
|
Phenylalanine | 1 | 2005 | 58 | 0.020 |
Why?
|
Carcinogens | 1 | 2005 | 105 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 1985 | 187 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1985 | 84 | 0.020 |
Why?
|
Haemophilus | 1 | 1965 | 4 | 0.020 |
Why?
|
Viral Proteins | 3 | 1981 | 283 | 0.020 |
Why?
|
Lymphokines | 1 | 1985 | 115 | 0.020 |
Why?
|
Mitomycins | 1 | 1984 | 3 | 0.020 |
Why?
|
Myeloma Proteins | 1 | 1984 | 7 | 0.020 |
Why?
|
Genes, MHC Class II | 1 | 1985 | 69 | 0.020 |
Why?
|
Endocytosis | 1 | 1986 | 152 | 0.020 |
Why?
|
Melphalan | 1 | 1984 | 29 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 1985 | 115 | 0.020 |
Why?
|
Exanthema | 1 | 2005 | 77 | 0.020 |
Why?
|
Carmustine | 1 | 1984 | 47 | 0.020 |
Why?
|
Monocytes | 2 | 1985 | 504 | 0.020 |
Why?
|
Tyrosine | 1 | 2005 | 218 | 0.020 |
Why?
|
Endocarditis, Bacterial | 1 | 1965 | 36 | 0.020 |
Why?
|
Syndrome | 3 | 1984 | 339 | 0.020 |
Why?
|
Cross Reactions | 1 | 1984 | 116 | 0.010 |
Why?
|
DNA Replication | 1 | 2005 | 204 | 0.010 |
Why?
|
Psychology, Child | 1 | 2004 | 37 | 0.010 |
Why?
|
Acute Disease | 2 | 1984 | 917 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 1301 | 0.010 |
Why?
|
Hemagglutination | 1 | 1964 | 7 | 0.010 |
Why?
|
Bronchopneumonia | 1 | 1964 | 5 | 0.010 |
Why?
|
Nephritis, Interstitial | 1 | 1984 | 7 | 0.010 |
Why?
|
DNA, Recombinant | 1 | 1984 | 42 | 0.010 |
Why?
|
Acetaminophen | 1 | 1987 | 237 | 0.010 |
Why?
|
Expectorants | 1 | 1964 | 24 | 0.010 |
Why?
|
Nephrosis, Lipoid | 1 | 1984 | 10 | 0.010 |
Why?
|
Hypersensitivity, Delayed | 1 | 1983 | 52 | 0.010 |
Why?
|
Prednisone | 1 | 1984 | 232 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2005 | 274 | 0.010 |
Why?
|
Fatigue | 1 | 2005 | 295 | 0.010 |
Why?
|
Densitometry | 2 | 1980 | 29 | 0.010 |
Why?
|
Chromosomes | 2 | 1982 | 85 | 0.010 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2003 | 15 | 0.010 |
Why?
|
Cell Transformation, Viral | 2 | 1984 | 24 | 0.010 |
Why?
|
Paraneoplastic Syndromes | 1 | 1983 | 13 | 0.010 |
Why?
|
Toxicology | 1 | 1964 | 36 | 0.010 |
Why?
|
Muscles | 3 | 1982 | 328 | 0.010 |
Why?
|
Virus Diseases | 1 | 1966 | 200 | 0.010 |
Why?
|
3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2003 | 17 | 0.010 |
Why?
|
Vital Capacity | 1 | 2004 | 279 | 0.010 |
Why?
|
Growth Hormone | 2 | 1954 | 99 | 0.010 |
Why?
|
Mycobacterium tuberculosis | 2 | 1957 | 268 | 0.010 |
Why?
|
Vitamins | 1 | 2004 | 151 | 0.010 |
Why?
|
Biopsy, Needle | 2 | 1982 | 183 | 0.010 |
Why?
|
Cloxacillin | 1 | 1963 | 1 | 0.010 |
Why?
|
Tuberculosis, Miliary | 3 | 1964 | 5 | 0.010 |
Why?
|
Furunculosis | 1 | 1962 | 1 | 0.010 |
Why?
|
Pneumococcal Infections | 2 | 1956 | 91 | 0.010 |
Why?
|
Sex Ratio | 1 | 1983 | 14 | 0.010 |
Why?
|
Razoxane | 1 | 1982 | 1 | 0.010 |
Why?
|
Drainage | 1 | 1964 | 151 | 0.010 |
Why?
|
Receptors, Bradykinin | 1 | 2002 | 4 | 0.010 |
Why?
|
Transfer Factor | 1 | 1983 | 24 | 0.010 |
Why?
|
Thymosin | 2 | 1980 | 5 | 0.010 |
Why?
|
Leukapheresis | 1 | 1983 | 25 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2003 | 88 | 0.010 |
Why?
|
Lymphocyte Activation | 3 | 1983 | 1056 | 0.010 |
Why?
|
Antilymphocyte Serum | 1 | 1983 | 66 | 0.010 |
Why?
|
Cell Membrane | 2 | 2002 | 682 | 0.010 |
Why?
|
Allergy and Immunology | 1 | 1964 | 56 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 1983 | 156 | 0.010 |
Why?
|
Pentosyltransferases | 1 | 1982 | 3 | 0.010 |
Why?
|
Streptococcal Infections | 1 | 1965 | 132 | 0.010 |
Why?
|
Nucleoside Deaminases | 1 | 1982 | 2 | 0.010 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 1982 | 5 | 0.010 |
Why?
|
Bacteriophages | 2 | 1961 | 76 | 0.010 |
Why?
|
Autopsy | 1 | 1983 | 86 | 0.010 |
Why?
|
Cysteine | 1 | 1964 | 173 | 0.010 |
Why?
|
Cells, Cultured | 7 | 1985 | 3916 | 0.010 |
Why?
|
Keratins | 1 | 2003 | 176 | 0.010 |
Why?
|
Adenosine Deaminase | 1 | 1982 | 26 | 0.010 |
Why?
|
Immunity, Cellular | 2 | 1984 | 263 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2004 | 522 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2004 | 169 | 0.010 |
Why?
|
Umbilical Cord | 1 | 2002 | 80 | 0.010 |
Why?
|
Aggression | 1 | 2004 | 186 | 0.010 |
Why?
|
Receptors, Fc | 1 | 1982 | 45 | 0.010 |
Why?
|
Agglutinins | 1 | 1962 | 2 | 0.010 |
Why?
|
Clinical Enzyme Tests | 1 | 1982 | 11 | 0.010 |
Why?
|
Abdominal Neoplasms | 1 | 1982 | 26 | 0.010 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1982 | 8 | 0.010 |
Why?
|
Phosphopyruvate Hydratase | 1 | 1982 | 30 | 0.010 |
Why?
|
Manipulation, Spinal | 1 | 2002 | 8 | 0.010 |
Why?
|
Sulfonamides | 2 | 1955 | 447 | 0.010 |
Why?
|
Caspases | 1 | 2003 | 245 | 0.010 |
Why?
|
Complement System Proteins | 2 | 1962 | 288 | 0.010 |
Why?
|
Rectal Diseases | 1 | 1981 | 17 | 0.010 |
Why?
|
Herpesvirus 4, Human | 2 | 1980 | 123 | 0.010 |
Why?
|
Bone Resorption | 1 | 1982 | 74 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1983 | 224 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2002 | 111 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 1983 | 201 | 0.010 |
Why?
|
Phenotype | 4 | 1984 | 2858 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2006 | 1129 | 0.010 |
Why?
|
Immune System | 1 | 1983 | 173 | 0.010 |
Why?
|
Glasgow Coma Scale | 1 | 2002 | 144 | 0.010 |
Why?
|
CD52 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
Oculomotor Muscles | 2 | 1951 | 40 | 0.010 |
Why?
|
Alemtuzumab | 1 | 2001 | 12 | 0.010 |
Why?
|
Zymosan | 1 | 1961 | 63 | 0.010 |
Why?
|
APUD Cells | 1 | 1980 | 1 | 0.010 |
Why?
|
Furocoumarins | 1 | 1980 | 8 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2001 | 256 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2000 | 38 | 0.010 |
Why?
|
Polysaccharides | 1 | 1961 | 79 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2000 | 133 | 0.010 |
Why?
|
Leukocytes | 2 | 1984 | 284 | 0.010 |
Why?
|
Amyloidosis | 1 | 1980 | 36 | 0.010 |
Why?
|
Intestinal Neoplasms | 1 | 1980 | 24 | 0.010 |
Why?
|
Hospitals, Chronic Disease | 2 | 1958 | 2 | 0.010 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 1980 | 72 | 0.010 |
Why?
|
Piperazines | 1 | 1982 | 313 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2001 | 105 | 0.010 |
Why?
|
Cytological Techniques | 1 | 1980 | 23 | 0.010 |
Why?
|
Biological Assay | 1 | 2001 | 114 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 1980 | 40 | 0.010 |
Why?
|
Soft Tissue Neoplasms | 1 | 1981 | 90 | 0.010 |
Why?
|
Antiviral Agents | 1 | 1966 | 648 | 0.010 |
Why?
|
Bacteremia | 1 | 1962 | 159 | 0.010 |
Why?
|
Hypersensitivity | 1 | 1964 | 272 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2002 | 319 | 0.010 |
Why?
|
Brain | 3 | 1985 | 2382 | 0.010 |
Why?
|
Health Resources | 1 | 2001 | 122 | 0.010 |
Why?
|
Influenza, Human | 1 | 1985 | 549 | 0.010 |
Why?
|
Disease Management | 1 | 1964 | 562 | 0.010 |
Why?
|
Range of Motion, Articular | 1 | 2002 | 353 | 0.010 |
Why?
|
Thymus Hormones | 1 | 1979 | 1 | 0.010 |
Why?
|
Joint Instability | 1 | 2002 | 166 | 0.010 |
Why?
|
Carcinogens, Environmental | 1 | 1979 | 6 | 0.010 |
Why?
|
Stomach Ulcer | 1 | 1979 | 9 | 0.010 |
Why?
|
Gastroscopy | 1 | 1979 | 18 | 0.010 |
Why?
|
Duodenal Ulcer | 1 | 1979 | 10 | 0.010 |
Why?
|
Osteoporosis | 1 | 1982 | 227 | 0.010 |
Why?
|
Spinal Cord | 1 | 1982 | 351 | 0.010 |
Why?
|
History, 19th Century | 1 | 1979 | 57 | 0.010 |
Why?
|
Glycoproteins | 1 | 2001 | 308 | 0.010 |
Why?
|
Neuroblastoma | 1 | 1980 | 130 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2002 | 545 | 0.010 |
Why?
|
Blood Platelets | 2 | 1984 | 350 | 0.010 |
Why?
|
Hybridomas | 2 | 1994 | 230 | 0.010 |
Why?
|
Spinal Cord Compression | 1 | 1978 | 17 | 0.010 |
Why?
|
Demeclocycline | 1 | 1978 | 3 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2000 | 388 | 0.010 |
Why?
|
Antigens, CD | 1 | 2001 | 442 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1998 | 29 | 0.010 |
Why?
|
Phospholipase C beta | 1 | 1998 | 26 | 0.010 |
Why?
|
Gastritis | 1 | 1979 | 84 | 0.010 |
Why?
|
Chloramphenicol | 1 | 1958 | 6 | 0.010 |
Why?
|
Practice Patterns, Physicians' | 1 | 2006 | 1177 | 0.010 |
Why?
|
Levamisole | 1 | 1998 | 20 | 0.010 |
Why?
|
Vasopressins | 1 | 1978 | 57 | 0.010 |
Why?
|
Estradiol | 1 | 1981 | 453 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1979 | 128 | 0.010 |
Why?
|
Antibody Specificity | 3 | 1983 | 180 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 1980 | 340 | 0.010 |
Why?
|
Cell Separation | 3 | 1986 | 293 | 0.010 |
Why?
|
Hormones, Ectopic | 1 | 1977 | 2 | 0.010 |
Why?
|
Occupational Diseases | 1 | 1979 | 129 | 0.010 |
Why?
|
Pregnancy | 1 | 1989 | 5555 | 0.010 |
Why?
|
Fluorouracil | 1 | 1998 | 151 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 1997 | 54 | 0.010 |
Why?
|
Thoracotomy | 1 | 1997 | 67 | 0.010 |
Why?
|
Amantadine | 2 | 1968 | 7 | 0.010 |
Why?
|
Vinca Alkaloids | 1 | 1976 | 1 | 0.010 |
Why?
|
Capsules | 1 | 1957 | 36 | 0.010 |
Why?
|
Genetic Markers | 1 | 1998 | 337 | 0.010 |
Why?
|
Cephalosporins | 2 | 1968 | 26 | 0.010 |
Why?
|
Immunoglobulin G | 2 | 1994 | 782 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1977 | 139 | 0.010 |
Why?
|
Penicillin V | 1 | 1956 | 3 | 0.010 |
Why?
|
Gentamicins | 2 | 1968 | 43 | 0.010 |
Why?
|
Cycloserine | 1 | 1956 | 3 | 0.010 |
Why?
|
Colchicine | 1 | 1976 | 24 | 0.010 |
Why?
|
Novobiocin | 1 | 1956 | 5 | 0.010 |
Why?
|
Maryland | 1 | 1996 | 37 | 0.010 |
Why?
|
Gallium Radioisotopes | 1 | 1975 | 19 | 0.010 |
Why?
|
Computer Communication Networks | 1 | 1996 | 33 | 0.010 |
Why?
|
Arthritis | 1 | 1957 | 110 | 0.010 |
Why?
|
Sulfisoxazole | 1 | 1955 | 1 | 0.010 |
Why?
|
Laparoscopy | 1 | 1980 | 400 | 0.010 |
Why?
|
Herpes Zoster | 1 | 1980 | 333 | 0.010 |
Why?
|
Glycopeptides | 1 | 1996 | 43 | 0.010 |
Why?
|
Cerebrospinal Fluid | 1 | 1976 | 88 | 0.010 |
Why?
|
Cyclic AMP | 1 | 1996 | 227 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 1956 | 133 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1997 | 609 | 0.010 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 1994 | 5 | 0.010 |
Why?
|
Portal System | 1 | 1953 | 13 | 0.010 |
Why?
|
Phlebitis | 1 | 1953 | 10 | 0.010 |
Why?
|
Respiratory Function Tests | 2 | 1986 | 541 | 0.010 |
Why?
|
Leucomycins | 1 | 1953 | 1 | 0.010 |
Why?
|
Dogs | 2 | 1987 | 344 | 0.010 |
Why?
|
Veins | 1 | 1953 | 57 | 0.010 |
Why?
|
Thyroid Gland | 1 | 1994 | 83 | 0.010 |
Why?
|
Isomerism | 1 | 1953 | 42 | 0.010 |
Why?
|
Heart Neoplasms | 1 | 1994 | 50 | 0.010 |
Why?
|
Gallamine Triethiodide | 1 | 1973 | 1 | 0.010 |
Why?
|
Edrophonium | 1 | 1973 | 2 | 0.010 |
Why?
|
Organ Specificity | 1 | 1994 | 273 | 0.010 |
Why?
|
Disease | 1 | 1953 | 83 | 0.010 |
Why?
|
Pulmonary Alveoli | 1 | 1996 | 376 | 0.010 |
Why?
|
Human Growth Hormone | 1 | 1953 | 38 | 0.010 |
Why?
|
Sciatic Nerve | 1 | 1973 | 56 | 0.010 |
Why?
|
Cats | 1 | 1973 | 205 | 0.010 |
Why?
|
Appendicitis | 1 | 1953 | 110 | 0.010 |
Why?
|
Chromosomes, Human, 1-3 | 2 | 1982 | 2 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 1992 | 80 | 0.010 |
Why?
|
Meningitis, Pneumococcal | 1 | 1952 | 7 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 2 | 1983 | 196 | 0.010 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 1992 | 9 | 0.010 |
Why?
|
Electric Stimulation | 1 | 1973 | 263 | 0.010 |
Why?
|
Recurrence | 3 | 1980 | 949 | 0.010 |
Why?
|
Models, Biological | 1 | 1979 | 1647 | 0.010 |
Why?
|
Hormones | 1 | 1952 | 132 | 0.010 |
Why?
|
Erythrocytes | 1 | 1976 | 590 | 0.010 |
Why?
|
Evaluation Studies as Topic | 2 | 1982 | 170 | 0.010 |
Why?
|
Insulin | 1 | 1981 | 2083 | 0.010 |
Why?
|
Perfusion | 1 | 1992 | 152 | 0.010 |
Why?
|
Klebsiella | 1 | 1970 | 2 | 0.010 |
Why?
|
Vestibulocochlear Nerve | 1 | 1970 | 6 | 0.010 |
Why?
|
Synaptic Transmission | 1 | 1973 | 232 | 0.010 |
Why?
|
Blood Cell Count | 2 | 1981 | 52 | 0.010 |
Why?
|
Organ of Corti | 1 | 1970 | 14 | 0.010 |
Why?
|
Chlortetracycline | 1 | 1950 | 4 | 0.010 |
Why?
|
Kidney | 2 | 1984 | 1208 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1970 | 66 | 0.010 |
Why?
|
Culture Media | 2 | 1981 | 156 | 0.010 |
Why?
|
Injections | 1 | 1991 | 163 | 0.010 |
Why?
|
Enterobacteriaceae Infections | 1 | 1970 | 33 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1982 | 406 | 0.010 |
Why?
|
Paralysis | 1 | 1970 | 67 | 0.010 |
Why?
|
Muscle Contraction | 1 | 1973 | 398 | 0.010 |
Why?
|
Action Potentials | 1 | 1973 | 408 | 0.010 |
Why?
|
Promegestone | 1 | 1989 | 33 | 0.010 |
Why?
|
Formaldehyde | 1 | 1989 | 47 | 0.010 |
Why?
|
Chickenpox | 1 | 1950 | 94 | 0.010 |
Why?
|
Vomiting | 2 | 1981 | 125 | 0.010 |
Why?
|
Neuromuscular Diseases | 1 | 1970 | 90 | 0.010 |
Why?
|
DNA Nucleotidyltransferases | 1 | 1968 | 11 | 0.000 |
Why?
|
Thrombocythemia, Essential | 1 | 1988 | 6 | 0.000 |
Why?
|
Polymyxins | 1 | 1968 | 9 | 0.000 |
Why?
|
Immunoglobulin Isotypes | 1 | 1987 | 32 | 0.000 |
Why?
|
Hepatic Insufficiency | 1 | 1947 | 4 | 0.000 |
Why?
|
Whole-Body Counting | 1 | 1987 | 4 | 0.000 |
Why?
|
Infant | 1 | 1980 | 8002 | 0.000 |
Why?
|
Lysosomes | 1 | 1968 | 126 | 0.000 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1988 | 93 | 0.000 |
Why?
|
Propidium | 1 | 1986 | 4 | 0.000 |
Why?
|
Medroxyprogesterone | 1 | 1986 | 10 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1970 | 355 | 0.000 |
Why?
|
Medroxyprogesterone Acetate | 1 | 1986 | 29 | 0.000 |
Why?
|
Coloring Agents | 1 | 1986 | 71 | 0.000 |
Why?
|
Orchiectomy | 1 | 1986 | 57 | 0.000 |
Why?
|
Cephaloridine | 1 | 1966 | 1 | 0.000 |
Why?
|
Immunoglobulin M | 1 | 1987 | 251 | 0.000 |
Why?
|
Immunodiffusion | 1 | 1965 | 9 | 0.000 |
Why?
|
Sulfanilamides | 2 | 1955 | 2 | 0.000 |
Why?
|
Spleen | 1 | 1987 | 491 | 0.000 |
Why?
|
Polymers | 1 | 1989 | 464 | 0.000 |
Why?
|
Immunization | 1 | 1987 | 402 | 0.000 |
Why?
|
Tuberculosis, Renal | 1 | 1964 | 1 | 0.000 |
Why?
|
Canada | 1 | 1965 | 337 | 0.000 |
Why?
|
Death, Sudden | 1 | 1964 | 33 | 0.000 |
Why?
|
Purines | 1 | 1985 | 159 | 0.000 |
Why?
|
Memory Disorders | 1 | 1985 | 155 | 0.000 |
Why?
|
Pathology | 1 | 1964 | 21 | 0.000 |
Why?
|
Polyethylene Glycols | 1 | 1989 | 576 | 0.000 |
Why?
|
Molecular Weight | 1 | 1984 | 335 | 0.000 |
Why?
|
Cell Differentiation | 2 | 1985 | 1706 | 0.000 |
Why?
|
Blood Cells | 1 | 1984 | 39 | 0.000 |
Why?
|
Urticaria | 1 | 1984 | 51 | 0.000 |
Why?
|
Leucovorin | 1 | 1983 | 42 | 0.000 |
Why?
|
Respiratory Tract Infections | 1 | 1968 | 323 | 0.000 |
Why?
|
West Indies | 1 | 1983 | 5 | 0.000 |
Why?
|
Alabama | 1 | 1983 | 28 | 0.000 |
Why?
|
Leukemia, Hairy Cell | 1 | 1983 | 6 | 0.000 |
Why?
|
Georgia | 1 | 1983 | 59 | 0.000 |
Why?
|
Florida | 1 | 1983 | 73 | 0.000 |
Why?
|
Aspartate Aminotransferases | 1 | 1983 | 87 | 0.000 |
Why?
|
Skin Tests | 1 | 1983 | 137 | 0.000 |
Why?
|
Warfarin | 1 | 1984 | 136 | 0.000 |
Why?
|
Osteosclerosis | 1 | 1982 | 2 | 0.000 |
Why?
|
Anemia, Sideroblastic | 1 | 1982 | 3 | 0.000 |
Why?
|
Pulmonary Embolism | 1 | 1964 | 182 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1982 | 295 | 0.000 |
Why?
|
Creatinine | 1 | 1983 | 431 | 0.000 |
Why?
|
Agranulocytosis | 1 | 1981 | 31 | 0.000 |
Why?
|
Adrenal Glands | 1 | 1982 | 72 | 0.000 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 1981 | 1 | 0.000 |
Why?
|
Peripheral Nerves | 1 | 1982 | 65 | 0.000 |
Why?
|
Viral Core Proteins | 1 | 1981 | 18 | 0.000 |
Why?
|
Diphosphates | 1 | 1981 | 16 | 0.000 |
Why?
|
Electrophysiology | 1 | 1982 | 202 | 0.000 |
Why?
|
Mental Disorders | 1 | 1949 | 908 | 0.000 |
Why?
|
Technetium | 1 | 1981 | 22 | 0.000 |
Why?
|
Transferrin | 1 | 1981 | 40 | 0.000 |
Why?
|
Nausea | 1 | 1981 | 103 | 0.000 |
Why?
|
Substance-Related Disorders | 1 | 1949 | 953 | 0.000 |
Why?
|
Abscess | 1 | 1981 | 73 | 0.000 |
Why?
|
Immune Sera | 1 | 1981 | 80 | 0.000 |
Why?
|
Fluorometry | 1 | 1980 | 19 | 0.000 |
Why?
|
Photomicrography | 1 | 1980 | 7 | 0.000 |
Why?
|
Microscopy, Phase-Contrast | 1 | 1980 | 18 | 0.000 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 1980 | 44 | 0.000 |
Why?
|
Dermatitis, Exfoliative | 1 | 1980 | 4 | 0.000 |
Why?
|
Haplorhini | 1 | 1980 | 59 | 0.000 |
Why?
|
Purpura | 1 | 1980 | 12 | 0.000 |
Why?
|
Castration | 1 | 1980 | 14 | 0.000 |
Why?
|
Macrophage Migration-Inhibitory Factors | 1 | 1980 | 14 | 0.000 |
Why?
|
Alopecia | 1 | 1979 | 28 | 0.000 |
Why?
|
Receptors, Complement | 1 | 1980 | 112 | 0.000 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 1980 | 102 | 0.000 |
Why?
|
Cocarcinogenesis | 1 | 1979 | 14 | 0.000 |
Why?
|
Chemical Industry | 1 | 1979 | 9 | 0.000 |
Why?
|
Methods | 1 | 1978 | 59 | 0.000 |
Why?
|
Fiber Optic Technology | 1 | 1978 | 17 | 0.000 |
Why?
|
Hemoglobins | 1 | 1981 | 313 | 0.000 |
Why?
|
Pesticides | 1 | 1979 | 49 | 0.000 |
Why?
|
Solvents | 1 | 1979 | 109 | 0.000 |
Why?
|
Mucous Membrane | 1 | 1978 | 108 | 0.000 |
Why?
|
Granulocytes | 1 | 1976 | 78 | 0.000 |
Why?
|
Herpesvirus 3, Human | 1 | 1980 | 381 | 0.000 |
Why?
|
Air Pollutants | 1 | 1979 | 285 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1983 | 2167 | 0.000 |
Why?
|
Hospitals, University | 1 | 1946 | 172 | 0.000 |
Why?
|
Biological Transport | 1 | 1946 | 373 | 0.000 |
Why?
|
Minnesota | 1 | 1964 | 134 | 0.000 |
Why?
|
Students | 1 | 1946 | 503 | 0.000 |
Why?
|